POU2F2-mediated upregulation of lncRNA PTPRG-AS1 inhibits ferroptosis in breast cancer via miR-376c-3p/SLC7A11 axis.

IF 3 4区医学 Q2 GENETICS & HEREDITY

Epigenomics Pub Date : 2024-02-01 Epub Date: 2024-02-06 DOI:10.2217/epi-2023-0100

Jun Li, Pei-Ting Li, Wei Wu, Bo-Ni Ding, Yan-Guang Wen, Hai-Lin Cai, Shuang-Xi Liu, Tao Hong, Jian-Fei Zhang, Jian-Da Zhou, Li-Yuan Qian, Juan Du

{"title":"POU2F2-mediated upregulation of lncRNA PTPRG-AS1 inhibits ferroptosis in breast cancer via miR-376c-3p/SLC7A11 axis.","authors":"Jun Li, Pei-Ting Li, Wei Wu, Bo-Ni Ding, Yan-Guang Wen, Hai-Lin Cai, Shuang-Xi Liu, Tao Hong, Jian-Fei Zhang, Jian-Da Zhou, Li-Yuan Qian, Juan Du","doi":"10.2217/epi-2023-0100","DOIUrl":null,"url":null,"abstract":"Background: Triple-negative breast cancer (TNBC) is a subtype of BC with high rates of mortality. The mechanism of PTPRG-AS1 in ferroptosis of TNBC was investigated. Methods: Chromatin immunoprecipitation and dual-luciferase reporter assays were used to measure intermolecular relationships. MTT and colony formation assays detected cell viability and proliferation. Kits detected Fe2+ and reactive oxygen species levels. The role of PTPRG-AS1 in tumor growth was analyzed in vivo. Results: PTPRG-AS1 was increased in TNBC tissues and cells. PTPRG-AS1 silencing increased the reduction of glutathione and GPX4, increased Fe2+ and reactive oxygen species in erastin-treated cells and inhibited proliferation. POU2F2 transcriptionally upregulated PTPRG-AS1. PTPRG-AS1 targeted miR-376c-3p to upregulate SLC7A11. PTPRG-AS1 knockdown suppressed tumor growth in vivo. Conclusion: POU2F2 transcriptionally activates PTPRG-AS1 to modulate ferroptosis and proliferation by miR-376c-3p/SLC7A11, promoting TNBC.","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"215-231"},"PeriodicalIF":3.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epigenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/epi-2023-0100","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Triple-negative breast cancer (TNBC) is a subtype of BC with high rates of mortality. The mechanism of PTPRG-AS1 in ferroptosis of TNBC was investigated. Methods: Chromatin immunoprecipitation and dual-luciferase reporter assays were used to measure intermolecular relationships. MTT and colony formation assays detected cell viability and proliferation. Kits detected Fe²⁺ and reactive oxygen species levels. The role of PTPRG-AS1 in tumor growth was analyzed in vivo. Results: PTPRG-AS1 was increased in TNBC tissues and cells. PTPRG-AS1 silencing increased the reduction of glutathione and GPX4, increased Fe²⁺ and reactive oxygen species in erastin-treated cells and inhibited proliferation. POU2F2 transcriptionally upregulated PTPRG-AS1. PTPRG-AS1 targeted miR-376c-3p to upregulate SLC7A11. PTPRG-AS1 knockdown suppressed tumor growth in vivo. Conclusion: POU2F2 transcriptionally activates PTPRG-AS1 to modulate ferroptosis and proliferation by miR-376c-3p/SLC7A11, promoting TNBC.

查看原文本刊更多论文

POU2F2介导的lncRNA PTPRG-AS1上调通过miR-376c-3p/SLC7A11轴抑制乳腺癌中的铁突变。

背景：三阴性乳腺癌（TNBC三阴性乳腺癌（TNBC）是 BC 中死亡率较高的一种亚型。研究人员探讨了 PTPRG-AS1 在 TNBC 铁变态反应中的作用机制。方法：染色质免疫沉淀使用染色质免疫沉淀和双荧光素酶报告实验来测量分子间的关系。MTT 和集落形成试验检测细胞活力和增殖。试剂盒检测了Fe2+和活性氧水平。在体内分析了 PTPRG-AS1 在肿瘤生长中的作用。结果PTPRG-AS1在TNBC组织和细胞中都有所增加。PTPRG-AS1沉默会增加谷胱甘肽和GPX4的还原，增加依拉斯汀处理细胞中的Fe2+和活性氧，并抑制细胞增殖。POU2F2 转录上调 PTPRG-AS1。PTPRG-AS1 靶向 miR-376c-3p 上调 SLC7A11。PTPRG-AS1 基因敲除抑制了肿瘤在体内的生长。结论POU2F2转录激活PTPRG-AS1，通过miR-376c-3p/SLC7A11调控铁变态反应和增殖，促进TNBC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Epigenomics GENETICS & HEREDITY-

CiteScore

5.80

自引率

2.60%

发文量

审稿时长

>12 weeks

期刊介绍： Epigenomics provides the forum to address the rapidly progressing research developments in this ever-expanding field; to report on the major challenges ahead and critical advances that are propelling the science forward. The journal delivers this information in concise, at-a-glance article formats – invaluable to a time constrained community. Substantial developments in our current knowledge and understanding of genomics and epigenetics are constantly being made, yet this field is still in its infancy. Epigenomics provides a critical overview of the latest and most significant advances as they unfold and explores their potential application in the clinical setting.